Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have heterogeneous outcomes; durable remissions are infrequently observed with standard approaches. Circulating tumor DNA (ctDNA) assessment is a sensitive, potentially prognostic tool in this setting. We assessed baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera, Alex F., Tracy, Samuel, Croft, Brandon, Opat, Stephen, Ray, Jill, Lovejoy, Alex F., Musick, Lisa, Paulson, Joseph N., Sehn, Laurie H., Jiang, Yanwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941482/
https://www.ncbi.nlm.nih.gov/pubmed/35086141
http://dx.doi.org/10.1182/bloodadvances.2021006415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941482/
https://www.ncbi.nlm.nih.gov/pubmed/35086141
http://dx.doi.org/10.1182/bloodadvances.2021006415

Ejemplares similares